Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic DLI after allo-PBSCT for high-risk hematologic malignancies
NCT03771222Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of donor lymphocyte infusion in hematologic malignancy, leukemia and lymphoma (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Cumulative incidence of relapse at 1 year and Non-relapse mortality at 1 year. Status: unknown.
02
Drugs
donor lymphocyte infusion
03
Conditions
hematologic malignancyleukemialymphoma
Beyond the preview
Go deeper on NCT03771222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03771222.